Last update 16 Oct 2026

HDM-2020

Overview

Basic Info

Drug Type
Antibody drug conjugate (ADC)
Synonyms
HDM 2020, HDM2020
Target
FGFR2b x Top I
Action
inhibitors
Mechanism
FGFR2b inhibitors(fibroblast growth factor receptor 2 IIIb inhibitors), TOP1 inhibitors(DNA topoisomerase I inhibitors)
Therapeutic Areas
NeoplasmsDigestive System DisordersRespiratory Diseases
Active Indication
Advanced Lung Non-Small Cell Squamous CarcinomaAdvanced Malignant Solid NeoplasmFGFR2 positive Stomach Cancer
Inactive Indication-
Originator Organization
Huadong Medicine Co., Ltd.Huadong Medicine Co., Ltd.
Active Organization
Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd.Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd.Huadong Medicine Co., Ltd.Huadong Medicine Co., Ltd.
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1
First Approval Date-
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC24H22FN3O4
InChIKeyZVYVPGLRVWUPMP-FYSMJZIKSA-N
CAS Registry171335-80-1
Boost your research with our ADC technology data.
login
or
view full example data
Boost your research with our ADC technology data.

Related

2
Clinical Trials associated with HDM-2020
NCT07638891
/ RecruitingPhase 1
A Phase Ib Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of HDM2020 in Patients With Advanced Squamous Non-small Cell Lung Cancer
NCT07098052
/ RecruitingPhase 1
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of HDM2020 (FGFR2b-ADC) in Patients With Advanced Solid Tumors
100 Clinical Results associated with HDM-2020
Login to view more data
100 Translational Medicine associated with HDM-2020
Login to view more data
100 Patents (Medical) associated with HDM-2020
Login to view more data
100 Deals associated with HDM-2020
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Lung Non-Small Cell Squamous CarcinomaPhase 1
China
Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd.Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd.
01 Apr 2026
Advanced Malignant Solid NeoplasmPhase 1
China
Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd.Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd.
01 Aug 2025
FGFR2 positive Stomach CancerPreclinical
China
Huadong Medicine Co., Ltd.Huadong Medicine Co., Ltd.
27 Apr 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
view full example data
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free